HypothyroidismNCT05015725
The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients
An observational study of Hypothyroidism, run by Semmelweis University at 1 site in Hungary.
Trial summary
The aim of this study is to evaluate the relationship between serum rT3 (serum reverse triiodothyronine) concentrations, T3/T4 (triiodothyronine/thyroxine) ratio, and persistent symptoms /quality of life in treated hypothyroid patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypothyroidism
- What is being tested?
- Quality of life assessment, biochemical measures
- How many people
- 262 participants
- Where
- 1 siteHungary
- Study dates
- 1 Aug 2021to 31 Aug 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patients treated for hypothyroidism with levothyroxine substitution.
Who may be able to join
- At least 18 years of age, inclusive, at the time of signing informed consent form.
- Hypothyroidism treated for >2 years
- TSH stable between 0.4 and 4.0 mIU/L for the past 6 months (at least 2 measurements)
Who cannot join
- Abnormal TSH on screening
- Unwilling or unable to participate/sign informed consent
- Changes in thyroxine dose or any other medication in the previous month
- Severe obesity (BMI [body mass index] >35kg/m2)
- Other significant comorbidity:
- History of ischaemic heart disease, valvular defect, stent placement, heart failure, stroke or TIA (transient ischemic attack)
Show all 11Show fewer
- Diabetes mellitus under OAD (oral antidiabetic drug) or insulin treatment
- eGFR (estimated glomerular filtration rate) <60ml/min at screening, calculated by EPI formula
- History of liver disease, AST/ALT>3 times normal or GGT (gamma-glutamil transferase) >2 times normal or hyperbilirubinaemia at screening
- Systemic autoimmune condition currently under treatment (RA [rheumatoid arthritis], lupus, systemic sclerosis etc.)
- Active malignancy
Trial locations and contacts
1 site in 1 country.
Hungary1 site
Semmelweis University - Departement Medicine and Oncology
Budapest, 1083
About this study
Official title: A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients
The aim of this study is to evaluate the relationship between serum rT3 (serum reverse triiodothyronine) concentrations, T3/T4 (triiodothyronine/thyroxine) ratio, and persistent symptoms /quality of life in treated hypothyroid patients.
Investigators are going to measure TSH (thyroid stimulating hormone), free-T3, free-T4, reverse-T3 levels, biochemical markers of hypothyroidism and quality of life (assessed by validated questionnaires).
Read the detailed description
Rationale: L-thyroxin (T4) substitution is the mainstay of treatment for hypothyroidism irrespective of disease origin. In a subset of patients with hypothyroidism however an inadequate peripheral T4->T3 conversion is hypostasized by some authors. This is speculated to lead to tissue level hypothyroidism and persistent symptoms even with adequate T4 replacement. As a potential pathogenetic mechanism, the inborn or acquired defect of peripheral deiodinases, decreased T3 and increased rT3 production is suggested.
Few results support this hypothesis. A decreased T3/T4 ratio has been reported in some post-surgical hypothyroid patients, while a few studies patient show increased patient satisfaction with combined T4+T3 substitution. However these differences have not been shown to be significant in large meta-analyses.
Due to the lack of convincing evidence current guidelines advocate against both routine rT3 measurement and T3 substitution. However in recent years, rT3 measurement and T3 supplementation has been steadily gaining popularity amongst some medical and functional medicine practitioners. Recent publications estimate order volume for rT3 tests in the US to be over 1 million per year. Thus, despite several decades of experience and multiple trials, the role of liothyronine (T3) substitution remains somewhat controversial.
The relationship between rT3 levels, T3/T4 ratio, quality of life and persistent symptoms of hypothyroidism in patients treated with adequate thyroxine doses has not been previously assessed.
A significant association of this nature would suggest the possibility of decreased peripheral T4->T3 conversion in some patients leading to worse treatment outcomes. A lack of relationship would further discredit the above detailed theories and could potentially help reduce the inadequate use of T3 substitution in patients.
Study population: Patients treated for hypothyroidism with no significant comorbidities are to be enrolled. Sample size calculations show adequate statistical power with over 150 participants. Based on the number of hypothyroid patients at our outpatient clinic, a sample size of 300-350 patients can reasonably be expected.
Schedule of activities: All study related procedures are performed during a single visit. These include recording of basic anthropometric data, a single draw of blood, and administration of psychological questionnaires. Laboratory tests include comprehensive thyroid function testing (TSH, T3, FT3, FT4, aTPO [anti-thyroperoxidase antibody]) with the addition of rT3 measurement. Less specific markers, associated with hypothyroidism are also assessed. These include serum cholesterol, CK (creatin-kinase), GOT/ASAT (aspartate-aminotransferase), GPT/ALAT (alanine-aminotransferase), creatinine and sodium levels. Psychological tests administered at the visit include ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables.
Statistical analysis: Statistical methods for this study possibly include correlation analysis, linear and logistic regression.
Objectives and endpoints: Current understanding of hypothyroidism and thyroid hormone replacement imply that treatment with thyroxine doses that are sufficient to the normalize TSH lead to adequate tissue T3 levels and euthyroid state in the whole body. An association however between quality of life and rT3, levels or T3/T4 ratio could point out patients that could potentially benefit from additional T3 replacement.
- Conditions
- Hypothyroidism
- Being tested
- Quality of life assessment, biochemical measures
- Keywords
- hypothyroidism, reverse T3, quality of life
- Medical subject headings
- Hypothyroidism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quality of life assessment, biochemical measuresDiagnostic test
Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables.
Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels.
| Study group | Role | What they receive |
|---|---|---|
| Treated hypothyroidism | Patients with treated hypothyroidism Receives: Diagnostic Test: Quality of life assessment, biochemical measures |
What is being measured
The primary outcome is the main question the study is designed to answer.
Association between rT3 level and quality of life
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and quality of life (QoL). For QoL assessment we are going to use the total points achieved on ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) tests.
Measured: baseline
Association between rT3 level and SASS result
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of Somatosensory Amplification Scale (SASS) questionnaire.
Measured: baseline
Association between rT3 level and ThySRQ result
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of ThySRQ questionnaire.
Measured: baseline
Association between rT3 level and ThyDQol result
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of ThyDQol questionnaire.
Measured: baseline
Secondary outcomes (6)
Association between rT3 and LDL-cholesterol level
Result of linear regression for evaluating the possible relation between serum reverse-T3 and LDL-cholesterol level.
Measured: baseline
Association between rT3 and CK level
Result of linear regression for evaluating the possible relation between serum reverse-T3 and creatin-kinase level.
Measured: baseline
Association between rT3 and GOT/ASAT level
Result of linear regression for evaluating the possible relation between serum reverse-T3 and GOT/ASAT level.
Measured: baseline
Association between rT3 and GPT/ALAT level
Result of linear regression for evaluating the possible relation between serum reverse-T3 and GPT/ALAT level.
Measured: baseline
Association between rT3 and eGFR level
Result of linear regression for evaluating the possible relation between serum reverse-T3 and eGFR level (eGFR will be calculated by using EPI formula).
Measured: baseline
Association between rT3 and sodium level
Result of linear regression for evaluating the possible relation between serum reverse-T3 and sodium level.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2021
- Study start1 Aug 2021
- Primary completion31 Aug 2022
- Study completion31 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypothyroidismStudies of the same condition, open and under way.
- More trials run by Semmelweis UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 262 participants (actual)
Sponsor and investigators
- Lead sponsor
- Semmelweis University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Istvan Takacs, Semmelweis University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05015725
- Sponsor's protocol ID
- RT3QoLSE
- Status last verified
- Oct 2022
- First submitted
- 30 Jun 2021
- Last updated
- 12 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients
- ClinicalTrials.gov ID
- NCT05015725
- Acronym / sponsor ID
- RT3QoLSE
- Conditions
- Hypothyroidism
- Keywords
- hypothyroidism, reverse T3, quality of life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 262 participants (actual)
- Lead sponsor
- Semmelweis UniversityUniversity, hospital or other
- Study start
- 1 Aug 2021 (actual)
- Primary completion
- 31 Aug 2022 (actual)
- Study completion
- 31 Aug 2022 (actual)
- First posted
- 20 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the relationship between serum rT3 (serum reverse triiodothyronine) concentrations, T3/T4 (triiodothyronine/thyroxine) ratio, and persistent symptoms /quality of life in treated hypothyroid patients.
Investigators are going to measure TSH (thyroid stimulating hormone), free-T3, free-T4, reverse-T3 levels, biochemical markers of hypothyroidism and quality of life (assessed by validated questionnaires).
Detailed description
Rationale: L-thyroxin (T4) substitution is the mainstay of treatment for hypothyroidism irrespective of disease origin. In a subset of patients with hypothyroidism however an inadequate peripheral T4->T3 conversion is hypostasized by some authors. This is speculated to lead to tissue level hypothyroidism and persistent symptoms even with adequate T4 replacement. As a potential pathogenetic mechanism, the inborn or acquired defect of peripheral deiodinases, decreased T3 and increased rT3 production is suggested.
Few results support this hypothesis. A decreased T3/T4 ratio has been reported in some post-surgical hypothyroid patients, while a few studies patient show increased patient satisfaction with combined T4+T3 substitution. However these differences have not been shown to be significant in large meta-analyses.
Due to the lack of convincing evidence current guidelines advocate against both routine rT3 measurement and T3 substitution. However in recent years, rT3 measurement and T3 supplementation has been steadily gaining popularity amongst some medical and functional medicine practitioners. Recent publications estimate order volume for rT3 tests in the US to be over 1 million per year. Thus, despite several decades of experience and multiple trials, the role of liothyronine (T3) substitution remains somewhat controversial.
The relationship between rT3 levels, T3/T4 ratio, quality of life and persistent symptoms of hypothyroidism in patients treated with adequate thyroxine doses has not been previously assessed.
A significant association of this nature would suggest the possibility of decreased peripheral T4->T3 conversion in some patients leading to worse treatment outcomes. A lack of relationship would further discredit the above detailed theories and could potentially help reduce the inadequate use of T3 substitution in patients.
Study population: Patients treated for hypothyroidism with no significant comorbidities are to be enrolled. Sample size calculations show adequate statistical power with over 150 participants. Based on the number of hypothyroid patients at our outpatient clinic, a sample size of 300-350 patients can reasonably be expected.
Schedule of activities: All study related procedures are performed during a single visit. These include recording of basic anthropometric data, a single draw of blood, and administration of psychological questionnaires. Laboratory tests include comprehensive thyroid function testing (TSH, T3, FT3, FT4, aTPO [anti-thyroperoxidase antibody]) with the addition of rT3 measurement. Less specific markers, associated with hypothyroidism are also assessed. These include serum cholesterol, CK (creatin-kinase), GOT/ASAT (aspartate-aminotransferase), GPT/ALAT (alanine-aminotransferase), creatinine and sodium levels. Psychological tests administered at the visit include ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables.
Statistical analysis: Statistical methods for this study possibly include correlation analysis, linear and logistic regression.
Objectives and endpoints: Current understanding of hypothyroidism and thyroid hormone replacement imply that treatment with thyroxine doses that are sufficient to the normalize TSH lead to adequate tissue T3 levels and euthyroid state in the whole body. An association however between quality of life and rT3, levels or T3/T4 ratio could point out patients that could potentially benefit from additional T3 replacement.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treated hypothyroidism | – | Diagnostic Test: Quality of life assessment, biochemical measuresPatients with treated hypothyroidism |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patients treated for hypothyroidism with levothyroxine substitution.
Key inclusion criteria (3 listed)
- At least 18 years of age, inclusive, at the time of signing informed consent form.
- Hypothyroidism treated for >2 years
- TSH stable between 0.4 and 4.0 mIU/L for the past 6 months (at least 2 measurements)
Key exclusion criteria (11 listed)
- Abnormal TSH on screening
- Unwilling or unable to participate/sign informed consent
- Changes in thyroxine dose or any other medication in the previous month
- Severe obesity (BMI [body mass index] >35kg/m2)
- Other significant comorbidity:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quality of life assessment, biochemical measuresPsychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to ~50 items including demographic variables. Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels. | Diagnostic test | Treated hypothyroidism |
Primary outcome
Association between rT3 level and quality of life
Time frame: baseline
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and quality of life (QoL). For QoL assessment we are going to use the total points achieved on ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) tests.
Association between rT3 level and SASS result
Time frame: baseline
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of Somatosensory Amplification Scale (SASS) questionnaire.
Association between rT3 level and ThySRQ result
Time frame: baseline
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of ThySRQ questionnaire.
Association between rT3 level and ThyDQol result
Time frame: baseline
Result of linear regression for evaluating the possible relation between serum reverse-T3 level and the result of ThyDQol questionnaire.
6 secondary outcomes
Association between rT3 and LDL-cholesterol level
Time frame: baseline
Association between rT3 and CK level
Time frame: baseline
Association between rT3 and GOT/ASAT level
Time frame: baseline
Association between rT3 and GPT/ALAT level
Time frame: baseline
Association between rT3 and eGFR level
Time frame: baseline
Association between rT3 and sodium level
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Oct 2022.
- Individual participant dataSharing planned: No
Related trials for Hypothyroidism
RecruitingObservational study
Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
Congenital Disorders of Glycosylation
Active, not recruitingPhase 4
Comparison of Two Timings of Levothyroxine Intake in Hypothyroid Patients: A Cross-over Randomized Control Trial
Hypothyroidism Primary
RecruitingObservational study
Understanding the Subnormal Rescue ofNeurological Development in Congenital Hypothyroidism (2022E5SZEM)
Congenital Hypothyroidism, Neurodevelopmental Disorders
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
Active, not recruitingPhase 2/3
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Hypothyroidism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypothyroidism, run by Semmelweis University at 1 site in Hungary.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association between rT3 level and quality of life (time frame: baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2022.